AEMD - Aethlon Medical, Inc.

NasdaqCM - NasdaqCM Real Time Price. Currency in USD
1.0300
0.0000 (0.00%)
As of 9:30AM EDT. Market open.
Stock chart is not supported by your current browser
Previous Close1.0300
Open1.0300
Bid0.9400 x 1400
Ask1.0000 x 1800
Day's Range1.0200 - 1.0300
52 Week Range0.7900 - 2.0400
Volume576
Avg. Volume84,421
Market Cap18.332M
Beta (3Y Monthly)1.69
PE Ratio (TTM)N/A
EPS (TTM)-0.3420
Earnings DateOct 31, 2018 - Nov 5, 2018
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est3.00
Trade prices are not sourced from all markets
  • GlobeNewswire5 days ago

    Investor Expectations to Drive Momentum within Aethlon Medical, Jaguar Animal Health, Advaxis, Forestar Group, Platform Specialty Products, and AVEO Pharmaceuticals — Discovering Underlying Factors of Influence

    NEW YORK, Oct. 18, 2018 -- In new independent research reports released early this morning, Market Source Research released its latest key findings for all current investors,.

  • PR Newswire7 days ago

    Aethlon Medical to Present at the 2018 BIO Investor Forum

    SAN DIEGO, Oct. 16, 2018 /PRNewswire/ -- Aethlon Medical, Inc. (AEMD), an immunotherapeutic technology company focused on unmet needs in global health, today announced that its CEO, Jim Joyce, will present at the 2018 BIO Investor Forum on Thursday, October 18, 2018 at 3:15 p.m. Pacific Time.  The event is being held at the Westin St. Francis Hotel in San Francisco, California.  A live audio webcast of the presentation can be accessed at http://www.aethlonmedical.com/news-media/presentations.  A replay of the webcast will be available until January 15, 2019. Aethlon Medical is focused on addressing unmet needs in global health.  The Aethlon Hemopurifier® is clinical-stage immunotherapeutic device candidate to combat cancer and life-threatening viral infections. Aethlon Medical is also the majority owner of Exosome Sciences, Inc., which is focused on the discovery of exosomal biomarkers to diagnose and monitor cancer and neurological disease progression.

  • Simply Wall St.14 days ago

    How Financially Strong Is Aethlon Medical Inc (NASDAQ:AEMD)?

    While small-cap stocks, such as Aethlon Medical Inc (NASDAQ:AEMD) with its market cap of US$20m, are popular for their explosive growth, investors should also be aware of their balance sheet Read More...

  • PR Newswirelast month

    Aethlon Medical Receives National Cancer Institute Award

    The Aethlon Hemopurifier is a first-in-class therapeutic technology designed for the rapid depletion of circulating viruses and cancer promoting exosomes. The FDA has designated the Hemopurifier as a "Breakthrough Device" for the treatment of life-threatening viruses for which there are no approved therapies.

  • Zacks Small Cap Research2 months ago

    AEMD: Compassionate Use, Real-World Data, Awaiting FDA Final Guidance

    Revenue of $150k represented the final payment from the phase I NCI cancer grant. A subsequent, phase 2 contract worth approximately $1.5M over two years, could follow – AEMD’s application for which is expected to be submitted later this year. Updates to several of the development programs were provided on the call, including that related to Hemopurifier under the Breakthrough Device designation, Hemopurifier’s potential role in cancer therapy and updates in the ESI segment – including CTE/TauSome study enrollment status and potential new opportunities.

  • GlobeNewswire2 months ago

    Research Report Identifies Ball, Aethlon Medical, NeoGenomics, Del Taco Restaurants, Arconic, and Agilysys with Renewed Outlook — Fundamental Analysis, Calculating Forward Movement

    NEW YORK, Aug. 27, 2018-- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of Ball ...

  • PR Newswire2 months ago

    Aethlon Medical Announces First Quarter Fiscal Year 2019 Results

    SAN DIEGO , Aug. 8, 2018 /PRNewswire/ -- Aethlon Medical, Inc. (Nasdaq: AEMD), a therapeutic technology company focused on unmet needs in global health and biodefense, today announced results for its fiscal ...

  • ACCESSWIRE2 months ago

    Aethlon Medical, Inc. to Host Earnings Call

    NEW YORK, NY / ACCESSWIRE / August 8, 2018 / Aethlon Medical, Inc. (NASDAQ: AEMD ) will be discussing their earnings results in their Q1 Earnings Call to be held on August 8, 2018 at 4:30 PM Eastern Time. ...

  • PR Newswire3 months ago

    Aethlon Medical To Release Financial Results for the First Quarter Fiscal Year 2019 and Host Conference Call on August 8, 2018

    SAN DIEGO , Aug. 2, 2018  /PRNewswire/ -- Aethlon Medical, Inc. (NASDAQ: AEMD), a therapeutic technology company focused on unmet needs in global health and biodefense today announced it will issue financial ...

  • Loss-Making Aethlon Medical Inc (NASDAQ:AEMD) Expected To Breakeven
    Simply Wall St.4 months ago

    Loss-Making Aethlon Medical Inc (NASDAQ:AEMD) Expected To Breakeven

    Aethlon Medical Inc’s (NASDAQ:AEMD): Aethlon Medical, Inc., a medical device company, focuses on creating devices that address unmet medical needs in health and biodefense worldwide. On 31 March 2018, theRead More...

  • PR Newswire4 months ago

    Guy Cipriani Joins Aethlon Medical's Board of Directors

    SAN DIEGO, June 25, 2018 /PRNewswire/ -- Aethlon Medical, Inc. (AEMD), a therapeutic technology company focused on unmet needs in global health and biodefense, today announced the appointment of Guy Cipriani to its Board of Directors. Mr. Cipriani qualifies as an independent director under the Nasdaq Rules. Mr. Cipriani is a business executive with nearly 20 years of experience in the pharmaceutical and biotech industries.

  • Zacks Small Cap Research4 months ago

    AEMD: AEMD In Active Discussions With FDA Regarding Hemopurifier Pathway

    Revenue of $75k, which was largely inline with our $89k estimate, relates entirely to a second milestone from the NCI cancer grant. Subsequent to the close of fiscal 2018, AEMD billed an additional $112k for work completed under this grant.

  • PR Newswire5 months ago

    Aethlon Medical Announces Fiscal 2018 Results

    SAN DIEGO , June 8, 2018 /PRNewswire/ -- Aethlon Medical, Inc. (Nasdaq: AEMD), a therapeutic technology company focused on unmet needs in global health and biodefense, today announced results for its fiscal ...

  • PR Newswire5 months ago

    Aethlon Medical To Release 2018 Fiscal Year End Financial Results and Host Conference Call on June 8, 2018

    Also Presenting at 2018 BIO International Convention on June 6, 2018 SAN DIEGO , May 31, 2018 /PRNewswire/ -- Aethlon Medical, Inc. (Nasdaq: AEMD), a therapeutic technology company focused on unmet needs ...

  • Are Aethlon Medical Inc’s (NASDAQ:AEMD) Interest Costs Too High?
    Simply Wall St.5 months ago

    Are Aethlon Medical Inc’s (NASDAQ:AEMD) Interest Costs Too High?

    Aethlon Medical Inc (NASDAQ:AEMD) is a small-cap stock with a market capitalization of US$21.04M. While investors primarily focus on the growth potential and competitive landscape of the small-cap companies, theyRead More...

  • ACCESSWIRE6 months ago

    GVC Capital and Trickle Research Announce Presenter Schedule for Rocky Mountain MicroCap Conference II in Denver on April 24, 2018

    DENVER, CO / ACCESSWIRE / April 20, 2018 / GVC Capital LLC ("GVC") and Dave Lavigne at Trickle Research LLC ("Trickle Research") will host the Rocky Mountain MicroCap Conference II ...

  • PR Newswire7 months ago

    Study of Blood Test to Detect and Monitor Chronic Traumatic Encephalopathy (CTE) in Former NFL Players Set for Kick-Off in Phoenix

    PHOENIX and SAN DIEGO, March 22, 2018 /PRNewswire/ -- Exosome Sciences, Inc., a diagnostic subsidiary of Aethlon Medical, Inc. (AEMD), today announced the initiation of an Institutional Review Board (IRB) approved protocol for a research study involving retired NFL players and a data-supported biomarker candidate to potentially detect and monitor Chronic Traumatic Encephalopathy (CTE) in living individuals. The sample collection will be conducted in collaboration with Kendall Van Keuren-Jensen, Ph.D., co-director of the Translational Genomics Research Institute's (TGen) Center for Noninvasive Diagnostics, for biomarker discovery projects. With the approval of the protocol, investigators plan to initiate screening of candidate participants in the coming weeks.  The study will enroll former NFL players, who are at high-risk of suffering from CTE, and control subjects who didn't participate in activities that involved repetitive head trauma.

  • PR Newswire8 months ago

    Aethlon Medical To Present at the American Society for Microbiology Biothreats Meeting

    SAN DIEGO, Feb. 12, 2018 /PRNewswire/ -- Aethlon Medical, Inc. (AEMD), a therapeutic technology company focused on unmet needs in global health and biodefense, announced today that its CEO, Jim Joyce will give a presentation at the 2018 American Society for Microbiology (ASM) Biothreats Meeting.  The presentation entitled: "A Broad-Spectrum Platform to Address Life-Threating Viral Infections," is scheduled to begin at 8:30am eastern on February 14th.  The presentation slide-deck will be made available on the Aethlon Medical website at https://www.aethlonmedical.com/news-media/presentations. The American Society for Microbiology Biothreats Meeting is being held today, February 12th through the 14th at the Hilton, Baltimore Md.  The event includes tracks on high consequence pathogen research, biological threat reduction, product development, and policy.

  • Zacks Small Cap Research9 months ago

    AEMD: Q3 Results. Hemopurifier Pathway Could Benefit From New FDA Mindset

    By Brian Marckx, CFA NASDAQ:AEMD Fiscal Q3 2018 Financials, Operational Update Aethlon Medical (NASDAQ:AEMD) reported financial results for their fiscal third quarter 2018 ending December 31st and provided ...

  • PR Newswire9 months ago

    Aethlon Medical Announces Fiscal 2018 Third Quarter Results

    SAN DIEGO , Feb. 1, 2018 /PRNewswire/ -- Aethlon Medical, Inc. (Nasdaq: AEMD), a therapeutic technology company focused on unmet needs in global health and biodefense, today announced results for its fiscal ...

  • PR Newswire9 months ago

    Aethlon Medical to Release Third Quarter Fiscal Year 2018 Financial Results and Host Conference Call on February 1, 2018

    SAN DIEGO , Jan. 29, 2018 /PRNewswire/ -- Aethlon Medical, Inc. (Nasdaq: AEMD), a therapeutic technology company focused on unmet needs in global health and biodefense today announced it will issue third ...

  • PR Newswire9 months ago

    Aethlon Medical Announces Validation Completion for European Patent Protecting Methods of Quantifying Exosomes

    SAN DIEGO, Jan. 23, 2018 /PRNewswire/ -- Aethlon Medical, Inc. (AEMD), a therapeutic technology company focused on unmet needs in global health and biodefense, announced today that validation has completed and the opposition period expired for European Patent Number 2591359, entitled "METHODS AND COMPOSITIONS FOR QUANTIFYING EXOSOMES." The patent was validated in Germany, France, Great Britain, and Spain. In recent years, exosomes have emerged as a significant diagnostic and therapeutic tool for a wide range of disease conditions, including cancer, tuberculosis, Alzheimer's, and chronic traumatic encephalopathy (CTE).